| 177.58 -12.72 (-6.68%) | 03-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 215.75 |
1-year : | 233.59 |
| Resists | First : | 184.72 |
Second : | 200 |
| Pivot price | 181.01 |
|||
| Supports | First : | 160 |
Second : | 133.11 |
| MAs | MA(5) : | 186.12 |
MA(20) : | 181.23  |
| MA(100) : | 141.16 |
MA(250) : | 94.89 |
|
| MACD | MACD : | 5.4 |
Signal : | 5.8 |
| %K %D | K(14,3) : | 70.4 |
D(3) : | 75.8 |
| RSI | RSI(14): 50.8 |
|||
| 52-week | High : | 200 | Low : | 49 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BLTE ] has closed above bottom band by 35.2%. Bollinger Bands are 13.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 188.32 - 189.28 | 189.28 - 190.02 |
| Low: | 171.21 - 172.16 | 172.16 - 172.89 |
| Close: | 176.05 - 177.67 | 177.67 - 178.91 |
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Mon, 02 Mar 2026
Belite Bio Q4 Earnings Call Highlights - Yahoo Finance
Mon, 02 Mar 2026
Belite Bio (NASDAQ:BLTE) Shares Down 8.6% - What's Next? - MarketBeat
Mon, 02 Mar 2026
Earnings call transcript: Belite Bio beats Q4 2025 EPS expectations, stock dips slightly - Investing.com
Mon, 02 Mar 2026
Assessing Belite Bio (BLTE) Valuation After Wider Fourth Quarter And Full Year Net Losses - simplywall.st
Mon, 02 Mar 2026
Belite Bio to Participate in the Leerink Global Healthcare Conference - bitget.com
Mon, 02 Mar 2026
Belite Bio, Inc Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 38 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 46.7 (%) |
| Held by Institutions | 19.5 (%) |
| Shares Short | 585 (K) |
| Shares Short P.Month | 330 (K) |
| EPS | -1.92 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.86 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -21.3 % |
| Return on Equity (ttm) | -32.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -31 (M) |
| Levered Free Cash Flow | 103 (M) |
| PE Ratio | -92.49 |
| PEG Ratio | 0 |
| Price to Book value | 22.59 |
| Price to Sales | 0 |
| Price to Cash Flow | -213.5 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|